CXCL1 and breast carcinoma: Ginsenoside panaxatriol reduces the activation of NF-κB in breast cancer cells and thus decreases the expression of chemokines, such as CXCL1 and CXC motif chemokine ligand 8 (CXCL8)/interleukin-8 (IL-8), increasing the effectiveness of paclitaxel [94].